What's happening
This bill requires the New York State Department of Health to seek federal guidance on Medicaid coverage for FDA-approved evidence-based mobile medical apps treating substance use and opioid use disorders.
Why it matters
Seeks to address a gap in Medicaid coverage for digital treatments. by pushing the state to clarify if federal funds can be used for FDA-approved mobile apps targeting substance and opioid use disorders, potentially paving the way for broader insurance coverage of these new therapies.
Recognizes the role of technology in addiction treatment,. especially post-COVID, highlighting that software-based interventions can be as rigorously tested and prescribed as traditional medications, but currently face regulatory barriers to coverage.
Could accelerate patient access to innovative care options. by prompting the Department of Health to formally engage with federal authorities, which may ultimately lead to faster adoption of evidence-based digital health tools for vulnerable populations.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expand Medicaid for Health Apps
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
- Referred to health
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
5812
2023-2024 Regular Sessions
IN SENATE
March 17, 2023
Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain evidence-based mobile medical applications
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Legislative findings and declaration. Within the past decade, it has become clear more needs to be done for New Yorkers with substance use disorders. From 2010 to 2021, the number of fatal drug overdoses in New York state alone increased from 1,557 to 5,841. This problem was only exacerbated by the COVID-19 pandemic, which was a relapse and addiction catalyst for many individuals. Evidence-based smartphone apps are new, software-based disease treatments designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. These therapies are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software. Certain evidence-based smartphone apps provide clinicians and patients with evidence-based remote treatment modalities to treat substance and opioid use disorders, mental health, and other diseases and conditions. However, there is no clear statutory benefit category to allow Medicaid coverage for evidence-based smartphone apps. In light of the promise of evidence-based smartphone apps for the treatment of patients with substance use and opioid use disorders during the COVID-19 pandemic, this legislation would require that the New York state department of health seek guidance from the Centers for Medicare and Medicaid Services relative to a coverage and reimbursement pathway for evidence-based smartphone apps, in order to accelerate access to such therapies for enrollees.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06394-02-3
§ 2. No later than 30 days from the effective date of this act, the New York state department of health shall request guidance from the Centers for Medicare and Medicaid Services to determine whether the state can claim federal financial participation for coverage of and payment for evidence-based mobile medical applications approved by the food and drug administration to treat substance use and opioid use disorders.
§ 3. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain evidence-based mobile medical applications
Purpose
Determines whether the state can claim federal financial participation for coverage of and payment for certain evidence-based mobile medical applications
Summary of provisions
Section 1 states the legislative findings.
Section 2 provides that no later than 30 days from the effective date the Department of Health shall request guidance from the Centers for Medicare and Medicaid Services to determine whether the state can claim federal financial participation for coverage of and payment for certain evidence-based mobile medical applications approved by the food and drug administration to treat substance use and opioid use disorders.
Section 3 states the effective date.
Justification
Within the past decade, it has become clear more needs to be done for New Yorkers with substance use disorders. From 2010 to 2021, the number of fatal drug overdoses in New York state alone increased from 1,557 to 5,841. This problem was only exacerbated by the COVID-19 pandemic, which was a relapse and addiction catalyst for many individuals. Evidence- based smartphone apps are new, software-based disease treatments designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. These therapies are designed and tested much like traditional prescription drugs with one distinction: rather than swal- lowing a pill or taking an injection, patients are treated with soft- ware. Certain evidence-based mobile medical applications provide clini- cians and patients with evidence-based remote treatment modalities to treat substance and opioid use disorders, mental health, and other diseases and conditions. However, there is no clear statutory benefit category to allow Medicaid coverage for evidence-based mobile medical applications.
In light of the promise of evidence-based smartphone apps for the treat- ment of patients with substance use and opioid use disorders following the coronavirus pandemic, this legislation would require that the New York state department of health seek guidance from the Centers for Medi- care and Medicaid Services relative to a coverage and reimbursement pathway for evidence-based smartphone apps, in order to accelerate access to such therapies for enrollees.
Legislative history
2021-2022: S6306: Died in Health
Fiscal implications
None to the State.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.